Patents by Inventor Johanna M. Jansen

Johanna M. Jansen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Quinazolines for PDK1 inhibition
    Patent number: 7932262
    Abstract: The invention provides quinazoline compounds that are inhibitors of PDK1. Also provided are pharmaceutical compositions including the compounds, and methods of treating proliferative diseases, such as cancers, with the compounds or compositions.
    Type: Grant
    Filed: April 5, 2007
    Date of Patent: April 26, 2011
    Assignee: Novartis AG
    Inventors: Savithri Ramurthy, Xiaodong Lin, Sharadha Subramanian, Alice Rico, Xiaojong M. Wang, Rama Jain, Jeremy M. Murray, Stephen E. Basham, Robert L. Warne, Wei Shu, Yasheen Zhou, Jeffrey Dove, Mina Aikawa, Payman Amiri, Weibo Wang, Johanna M. Jansen, Allan S. Wagman, Keith B. Pfister, Simon Ng
  • QUINAZOLINES FOR PDK1 INHIBITION
    Publication number: 20100048561
    Abstract: The invention provides quinazoline compounds that are inhibitors of PDK1. Also provided are pharmaceutical compositions including the compounds, and methods of treating proliferative diseases, such as cancers, with the compounds or compositions.
    Type: Application
    Filed: April 5, 2007
    Publication date: February 25, 2010
    Applicant: NOVARTIS VACCINES & DIAGNOSTICS, INC.
    Inventors: Savithri Ramurthy, Xiaodong Lin, Sharadha Subramanian, Alice C. Rico, Xiaojing M. Wang, Rama Jain, Jeremy M. Murray, Steven E. Basham, Robert L. Warne, Wei Shu, Yasheen Zhou, Jeffrey Dove, Mina Aikawa, Payman Amiri, Weibo Wang, Johanna M. Jansen, Allan S. Wagman, Keith B. Pfister, Simon Ng
  • Indazole benzimidazole compounds
    Patent number: 7642278
    Abstract: Organic compounds having the structure I are provided where the variables have the values described herein. A method of inhibiting c-ABL in a patient includes administering an effective amount of a compound of structure I, a tautomer of the compound, a pharmaceutically acceptable salt of the compound, or a pharmaceutically acceptable salt of the tautomer to the patient.
    Type: Grant
    Filed: October 27, 2005
    Date of Patent: January 5, 2010
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Johanna M. Jansen, Christopher McBride, Paul A. Renhowe, Cynthia Shafer
  • Benzimidazole quinolinones and uses thereof
    Publication number: 20090281100
    Abstract: Methods of inhibiting various enzymes and treating various conditions are provided that include administering to a subject a compound of Structure I or IB, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I and IB have the following structures and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting various enzymes and for use in treating conditions mediated by such enzymes.
    Type: Application
    Filed: December 23, 2008
    Publication date: November 12, 2009
    Inventors: Paul A. Barsanti, Dirksen Bussiere, Stephen D. Harrison, Carla C. Heise, Johanna M. Jansen, Elisa Jazan, Timothy D. Machajewski, Christopher McBride, William R. McCrea, JR., Simon Ng, Zhi-Jie Ni, Sabina Pecchi, Keith B. Pfister, Savithri Ramurthy, Paul A. Renhowe, Cynthia M. Shafer, Joel B. Silver, Allan S. Wagman, Marion Wiesmann, Kelly Wayman
  • Benzimidazole quinolinones and uses thereof
    Patent number: 7470709
    Abstract: Methods of inhibiting various enzymes and treating various conditions are provided that include administering to a subject a compound of Structure I or IB, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I and IB have the following structures and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting various enzymes and for use in treating conditions mediated by such enzymes.
    Type: Grant
    Filed: August 19, 2003
    Date of Patent: December 30, 2008
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Paul A. Barsanti, Dirksen Bussiere, Stephen D. Harrison, Carla C. Heise, Johanna M. Jansen, Elisa Jazan, Timothy D. Machajewski, Christopher McBride, William R. McCrea, Jr., Simon Ng, Zhi-Jie Ni, Sabina Pecchi, Keith B. Pfister, Savithri Ramurthy, Paul A. Renhowe, Cynthia M. Shafer, Joel B. Silver, Allan S. Wagman, Marion Wiesmann, Kelly Wayman
  • Characterization of the gsk-3beta protein and methods of use thereof
    Publication number: 20040101907
    Abstract: The invention provides the three-dimensional structure of a construct of human glycogen synthase kinase 3 (GSK3); crystals of a construct of human glycogen synthase kinase 3-&bgr; (GSK3-&bgr;); containing the protein's catalytic kinase domain; a domain for crystallizing the protein construct to provide a GSK3 crystal sufficient for structure determination; and a method for using the GSK3 construct's three dimensional structure for the identification of possible therapeutic compounds in the treatment of various disease conditions mediated by GSK3 activity.
    Type: Application
    Filed: December 11, 2003
    Publication date: May 27, 2004
    Inventors: Dirksen E. Bussiere, Min He, Vincent P Le, Johanna M Jansen, S Michael Chin, Eric Martin
  • Benzimidazole quinolinones and uses thereof
    Publication number: 20040092535
    Abstract: Methods of inhibiting various enzymes and treating various conditions are provided that include administering to a subject a compound of Structure I or IB, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I and IB have the following structures and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting various enzymes and for use in treating conditions mediated by such enzymes.
    Type: Application
    Filed: August 19, 2003
    Publication date: May 13, 2004
    Applicant: Chiron Corporation
    Inventors: Paul A. Barsanti, Dirksen Bussiere, Stephen D. Harrison, Carla C. Heise, Johanna M. Jansen, Elisa Jazan, Timothy D. Michajewski, Christopher McBride, William R. McCrea, Simon Ng, Zhi-Jie Ni, Sabina Pecchi, Keith B. Pfister, Savithri Ramurthy, Paul A. Renhowe, Cynthia M. Shafer, Joel B. Silver, Allan S. Wagman, Marion Wiesmann